Neutralizing antibodies against TSLP or IL-1 receptor-like 1 (IL1RL1), which is the receptor for IL-33 and which is also known as suppression of tumorigenicity 2 (ST2), reduced phenotypic features of TH2 inflammation induced by ILC2 in obese mice with antigen-induced lung inflammation without impacting features of neutrophilic inflammation [84]. Here, IL1RL1 is linked to inflammation.